Investment banks lift Broadcom price targets after strong results

Investing.com
Updated
Mitrade
coverImg
Source: DepositPhotos

Investing.com - Broadcom (NASDAQ:AVGO) released impressive quarterly results earlier this week, and a number of investment banks have responded positively, raising their price targets as a result.


The chipmaker raised its forecast for annual revenue from AI-linked chips to $11 billion from $10 billion, raised its annual revenue and core profit projections and announced a 10-for-1 stock split.


The rising adoption of generative AI has been driving demand for companies such as Broadcom that provide chips and networking tools to support these intensive applications.


Its stock closed Thursday at $1,678.52, having gained over 12% on the day and over 50% year-to-date.


Deutsche Bank  (ETR:DBKGn) has lifted its 12-month price target to $1,900 from $1,400, and EPS estimates, while keeping a ‘buy’ rating.


“Overall, we believe AVGO [Broadcom] remains one of the most attractive options within the semiconductor industry, having a strong exposure to the AI megatrend, a core business primed for a cyclical rebound, and growth/synergy potential within the recently acquired VMware (NYSE:VMW),” analysts at the German bank said, in a note dated June 13.


JPMorgan (NYSE:JPM) also lifted its year-end price target, to $2,000 from $1,700, raising its forward estimates, while maintaining an ‘overweight’ rating.

“Overall, the team continues to drive a stable revenue growth profile even in a period of macro volatility given its portfolio breadth/diversification/product cycles,” JPMorgan said, in a note dated June 13.


Goldman Sachs (NYSE:GS) has also lifted its 12-month price target to $1,850, from $1,550, while also increasing its FY2024-26 revenue and non-GAAP EPS estimates, on average, by 7% and 6%, respectively.


The bank maintained a ‘buy’ rating.


“Alongside Nvidia (NASDAQ:NVDA), we view Broadcom as a critical piece to the ongoing AI infrastructure build-out,” analysts at Goldman said, in a note dated June 13.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Netflix Q3 Earnings Preview: Double Growth in Revenue and Profit Expected Amid Wall Street's Universal OptimismStreaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
Author  TradingKey
12 hours ago
Streaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
placeholder
Dow Jones futures rise due to easing US-China trade tensions, Fed rate cut betsDow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
Author  FXStreet
13 hours ago
Dow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
placeholder
Japan and Korea Lead Asian Stock Surge — Nikkei 225 Breaks 49,000, KOSPI Tops 3,800Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
Author  TradingKey
14 hours ago
Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
placeholder
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to OzempicOn Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
Author  TradingKey
Oct 17, Fri
On Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
placeholder
Are European Stocks Peaking? SocGen,Citi Turn Bearish on Q4, U.S. Regional Bank Crisis Adds New RiskA series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
Author  TradingKey
Oct 17, Fri
A series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
Real-time Quote